Skip to main content
Caplight Logo









PATH EX, Inc.

PATH EX, Inc.

Private
Houston, TexasHealthcare & Life Scienceshttps://pathex.co/

Last Round

Series A

Apr 25, 2025

Total Funding Raised

$6.88M

Company Overview

PATH EX, Inc. is a medical device company developing CycloPE®, a blood purification device designed to directly capture and remove bacteria from the bloodstream to treat sepsis.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

sepsis treatmentextracorporeal blood cleansingblood purificationmedical devicepathogen removalendotoxin removalblood filtrationbacteremia treatmentcritical care technologymicrobial identificationblood dialysissepsis managementFDA breakthrough device

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PATH EX, Inc. Comparables

Compare PATH EX, Inc. with similar companies based on industry and business-model similarity.

PATH EX, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BOA Biomedical Inc.
88%
Hemotune AG
84%
Cala Medical
84%

PATH EX, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 25, 2025
GrantSep 23, 2021
SeedOct 1, 2020
GrantJun 1, 2018
GrantJul 1, 2017

Key People

Founding team and executive leadership

Sinead E. Miller

CEO And Cofounder

Founding Team

Alex Wieseler

COO

Executive Team

PATH EX, Inc. Investors

Notable investors and investment history

PATH EX, Inc. investors
InvestorRounds
MedTech InnovatorGrant
IAG Capital PartnersSeries A
ZeroTo510Accelerator
MassChallenge IsraelSeed
Texas Medical CenterSeries A
AdvaMed AccelGrant
Fitz Gate VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Monthly visitors increased 152% MoM, reaching 1K.

  • Jun 1, 2018

    Received $910K from the National Science Foundation.

PATH EX, Inc. Filings

Explore SEC and related filing metadata, where available.

PATH EX, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about PATH EX, Inc.'s valuation, stock price, and market status.

Is PATH EX, Inc. a public or private company?

PATH EX, Inc. is a private company.

What is the current stock price of PATH EX, Inc.?

PATH EX, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is PATH EX, Inc. worth (valuation)?

Valuation information for PATH EX, Inc. is not publicly available.

Can I buy PATH EX, Inc. stock?

PATH EX, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was PATH EX, Inc.'s last funding round?

PATH EX, Inc.'s most recent funding round was Series A on April 25, 2025.

Who are the main investors in PATH EX, Inc.?

Key investors in PATH EX, Inc. include IAG Capital Partners.

Will PATH EX, Inc. IPO soon?

No public IPO plans have been announced for PATH EX, Inc..

How can I track PATH EX, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor PATH EX, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHouston, Texas
Employee Range4
Year Founded2017
Last FundingApr 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?